Evidence map›Paper›PMID 28392556›Full record

ArticleInternational journal of obesity (2005)2017

Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure.

J E Coborn, D P DePorter, V Mavanji, C M Sinton, C M Kotz, C J Billington, J A Teske

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of obesity (2005), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Connecting insufficient sleep and insomnia with metabolic dysfunction.Annals of the New York Academy of Sciences · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Orexins, Sleep, and Blood Pressure.Current hypertension reports · 2018
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

J E CobornDepartment of Nutritional Sciences, University of Arizona, Tucson, AZ, USA.
D P DePorterDepartment of Nutritional Sciences, University of Arizona, Tucson, AZ, USA.
V MavanjiMinneapolis VA Health Care System, Minneapolis, MN, USA.
C M SintonArizona Respiratory Center, University of Arizona, Tucson, AZ, USA.
C M KotzMinneapolis VA Health Care System, Minneapolis, MN, USA.
C J BillingtonMinneapolis VA Health Care System, Minneapolis, MN, USA.
J A TeskeDepartment of Nutritional Sciences, University of Arizona, Tucson, AZ, USA.
University of Arizona · USMinneapolis VA Health Care System · USGeriatric Research Education and Clinical Center · USUniversity of Minnesota · US

Funding

Role of Variability in SPA in Susceptibility to ObesityR01DK100281 · NIDDK · UNIVERSITY OF MINNESOTA · PI KOTZ, CATHERINE M · 2014 to 2017
$1.1M
Pre-clinic model for sleep deprivation-induced obesity and hedonic intake due to noise exposureR21NS099468 · NINDS · UNIVERSITY OF ARIZONA · PI TESKE, JENNIFER ANN · 2017 to 2018
$416k
Enhancing NEAT to Treat ObesityI01RX000441 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI BILLINGTON, CHARLES J., KOTZ, CATHERINE M · 2012 to 2015
–
NIDDK NIH HHS R01 DK100281NINDS NIH HHS R21 NS099468RRD VA I01 RX000441
6 · The paper itself

Abstract

backgroundIdentifying whether components of total energy expenditure (EE) are affected by orexin receptor (OXR1 and OXR2) stimulation or antagonism with dual orexin receptor antagonists (DORAs) has relevance for obesity treatment. Orexin receptor stimulation reduces weight gain by increasing total EE and EE during spontaneous physical activity (SPA).

objectiveThe purpose of this study was to determine if a DORA (TCS-1102) in the ventrolateral preoptic area (VLPO) reduced orexin-A-induced arousal, SPA, total EE and EE during sleep, rest, wake and SPA and whether the DORA alone reduced total EE and its components. We hypothesized that: (1) a DORA would reduce orexin-A induced increases in arousal, SPA, components of total EE, reductions in sleep and the EE during sleep and (2) the DORA alone would reduce baseline (non-stimulated) SPA and total EE. SUBJECTS/

methodsSleep, wakefulness, SPA and EE were determined after microinjection of the DORA (TCS-1102) and orexin-A in the VLPO of male Sprague-Dawley rats with a unilateral cannula targeted towards the VLPO. Individual components of total EE were determined based on time-stamped data.

resultsThe DORA reduced orexin-A-induced increases in arousal, SPA, total EE and EE during SPA, wake, rest and sleep 1 h post injection (P<0.05). Orexin-A significantly reduced sleep and significantly increased EE during sleep 1 h post injection (P<0.05). Furthermore, the DORA alone significantly reduced total EE, EE during sleep (NREM and REM) and resting EE 2 h post injection (P<0.05).

conclusionsThese data suggest that orexin-A reduces weight gain by stimulating total EE through increases in EE during SPA, rest and sleep. Residual effects of the DORA alone include decreases in total EE and EE during sleep and rest, which may promote weight gain.

Indexed as

AnimalsEnergy MetabolismIntracellular Signaling Peptides and ProteinsMaleObesityOrexin Receptor AntagonistsOrexinsPreoptic AreaRatsRats, Sprague-DawleySleepWakefulnessWeight GainIntracellular Signaling Peptides and ProteinsOrexin Receptor AntagonistsOrexins

Identifiers

PMID28392556
PMCPMC6893852
OpenAlexW2605643675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.